Strateos's experienced and diverse leadership team deeply believe in the core mission to turn biology into an information technology. Together they form a highly efficient team spanning biology, automation, and software engineering that guide the fantastic team of people that is Strateos.
Mark Fischer-Colbrie became CEO of Strateos in May 2019 following the successful sale of Labcyte Inc., a global laboratory tools company, to Danaher. He has more than 30 years of experience in building and growing laboratory tools, diagnostic, medical device and therapeutic companies, including 3 Initial Public Offerings. In 2013, Mark was named National Finalist, Life Sciences for the Ernst & Young National Entrepreneur of the Year and Entrepreneur of the Year, Life Sciences for Northern California. Prior to Strateos, Mark was CEO for over ten years at Labcyte Inc. which invented novel lab tools and automation based on acoustic dispensing. Before Labcyte, Mark ran business development and was CFO at Adeza Biomedical Corporation, a women’s healthcare company, where he filed 9 patent applications and set up and ran clinical trials for diagnostics. Prior to Adeza, Mark was the CFO for 9 years for a vision correction company that went public and launched a Class III medical device. Mark holds a BA from Stanford and an MBA in marketing / finance from UC Berkeley. Mark has served as Chairman of JDRF’s International Board of Directors, the largest global funder of type one diabetes research, and served on the JDRF IBOD for seven years. Mark has also served on the industry board of the Analytical, Life Sciences Diagnostics Association (ALDA) since 2011. Mark enjoys participating in long distance triathlon and running events.
Daniel Sipes joined Strateos in March 2019 to lead the San Diego operations. Prior to Strateos, he was the Director of Advanced Automation Technologies at the Genomics Institute of the Novartis Research Foundation. In this role, he was responsible for development of hardware and assay technologies to support large-scale cellular profiling and high-throughput screening efforts. He is an active member of SLAS, served as co-chair of SLAS2012, and has chaired tracks and sessions at numerous scientific conferences in the past. Sipes holds an M.S. degree in immunology from the University of California, Davis, where he focused on molecular biology. He also holds a B.S. degree in molecular biology with a minor in chemistry from California State University, Sacramento.
Alok Gupta joined Strateos in May 2019 to lead the engineering group. Alok has 20+ years of experience in building world-class software, as well as leading product development and architecture across various technology segments and industries. His experience includes working with startups and enterprises. As engineering leader, he is responsible for all aspects of engineering, including user experience, automation engineering, data fusion, autonomy, and interactive application. He has a BS from IIT, Varanasi, India.
Navid Farahani is Chief Medical Information Officer and the Head of Tissue Technologies and joined Strateos in July 2016. He holds a BS in Mechanical Engineering from the University of California San Diego and a Medical Degree from Ben Gurion University of the Negev. He trained as an Anatomic & Clinical Pathologist at Cedars-Sinai Medical Center followed by subspeciality training in Clinical Informatics at the University of Pittsburgh Medical Center. At UPMC, Navid's research focused on AI, mixed reality and 3D imaging techniques for pathologists. He also has a firm interest in high-fidelty tissue preservation and is a Scientific Advisor for the Brain Preservation Foundation.
As an undergraduate at the University of Pennsylvania more than a decade ago, Jimmy Sastra worked in a traumatic brain injury lab where he learned that wet lab biology requires lots of tedious human labor and could greatly benefit from automation. This experience prompted him to get a PhD at the Penn Modlab, where he built modular robots. He then worked at Willow Garage, where Jimmy designed different body parts for a humanoid robot. He joined Strateos from the Open Source Robotics Foundation, where he worked in mechanical engineering.
Ben Miles, Ph.D is a chemical biologist and product manager who has been working with Strateos since 2016. As product manager and a former customer of Strateos Ben works closely with our users and our internal team to ensure Strateos builds value for everyone of our users. As a scientist Ben is able to work closely with our users to understand their research requirements and synthesize those into the Strateos platform. Prior to Strateos, Ben worked in growth for the cloud-based electronic medical record company, Dentally, based in London, UK. Ben received a Ph.D and Master of Research in chemical biology from Imperial College London and also holds a B.Sc in Nanotechnology from the University of Leeds.
Chris Krueger joined Strateos in July of 2018 and brings more than 20 years of finance experience. In his current role he overseas all aspects of finance operations of the company. Previously, Chris served as SVP Finance and Operations at Vineti, a cloud based platform for the commercialization of cell & gene therapies, where he was responsible for the companies G&A organization. Prior to that role he served in multiple senior finance leadership roles at Grand Rounds, Flite (acquired by Snap), Avid Technologies and Digidesign. He started his career as a management trainee Mahle GmbH and later Siemens Semiconductor (now Infineon Technologies). Chris holds a bachelor of arts from the University of Michigan and a MBA from the Middlebury Institute of International Studies.
Kevin Sturdevant has more than a decade of experience in leading projects, products, and cross-functional teams in client-facing roles. His product experience includes learning management systems, mobile apps, and social media platforms while his project management experience includes delivering data workflow projects for Fortune 100 organizations. Prior to Strateos, Kevin led a Professional Services organization at Captricity, an Oakland-based SaaS product, and a Columbus, Ohio-based design and development agency.
Armen brings the perspective of an entrepreneur and startup co-founder, a product marketer at Fortune 500 healthcare companies, and an investor to DCVC. He leverages these diverse experiences to guide DCVC portfolio companies in their growth, focusing specifically on those in healthcare and biotech. Armen’s operational experience spans across medical devices, pharmaceuticals, insurance, and compute-driven startups in healthcare. Early in his career, he developed an online pharmacy for one of the first patient health record companies. He then spent several years in product management and early market development for first-in-class technologies at Guidant, Edwards Lifesciences, and Evalve (acquired by Abbott Laboratories). After Abbott, he co-founded DCVC company BlueTalon, which was initially focused on enterprise data security for data-driven clinical trial design and population health management. In addition to his operating role, Armen also leverages his unique cross-industry experience in technology and healthcare to identify new high potential startups for investment at the intersection of deep compute/Big Data and the life sciences. Armen received a M.S. in Management Science from Stanford University and a S.B. in Biomechanical Engineering and a Minor in French from Massachusetts Institute of Technology.
Jeff Finer joined Strateos’s Board of Directors in May 2018, and he brings more than 30 years of research and clinical experience including more than 20 years of industry experience leading drug discovery programs, technology development initiatives, preclinical development, and translational medicine. Dr. Finer is currently a Venture Partner at Third Rock Ventures where he is involved in founding and launching new biotech companies (including Maze Therapeutics and Ambys Medicines). Prior to joining Third Rock, Dr. Finer spent several years in R&D leadership positions including Vice President of Research Technology at Theravance Biopharma, Vice President, Discovery at Five Prime Therapeutics, and Director, Drug Discovery Technologies at Cytokinetics. Dr. Finer has focused his career on breakthrough innovations that have included moving several first-in-class drugs into the clinic and developing novel technology platforms which integrate science, instruments, and informatics. Dr. Finer obtained his MD and PhD in Biochemistry from Stanford University School of Medicine prior to residency training in Internal Medicine at Stanford and in Ophthalmology at Massachusetts Eye & Ear Infirmary and Harvard Medical School. He holds BS degrees in Chemistry and Biology from Massachusetts Institute of Technology.
Josh co-founded Lux Capital to support scientists and entrepreneurs who pursue counter-conventional solutions to the most vexing puzzles of our time in order to lead us into a brighter future. The more ambitious the project, the better—like, say, creating matter from light. Josh is a Director at Shapeways, Strateos, Lux Research, Kallyope, CTRL-labs, and Variant and helped lead the firm’s investments in Anduril, Planet, Echodyne, Clarifai and Authorea. He is a founding investor and board member with Bill Gates in Kymeta, making cutting-edge antennas for high-speed global satellite and space communications. Josh is a Westinghouse semi-finalist and published scientist. He previously worked in investment banking at Salomon Smith Barney and in capital markets at Merrill Lynch. In 2008 Josh co-founded and funded Kurion, a contrarian bet in the unlikely business of using advanced robotics and state-of-the-art engineering and chemistry to clean up nuclear waste. It was an unmet, inevitable need with no solution in sight. The company was among the first responders to the Fukushima Daiichi disaster. In February 2016, Veolia acquired Kurion for nearly $400 million—34 times Lux’s total investment. Josh is a columnist with Forbes and Editor for the Forbes/Wolfe Emerging Tech Report. He has been invited to The White House and Capitol Hill to advise on nanotechnology and emerging technologies, and a lecturer at MIT, Harvard, Yale, Cornell, Columbia and NYU. He is a term member at The Council on Foreign Relations and Chairman of Coney Island Prep charter school, where he grew up in Brooklyn. He graduated from Cornell University with a B.S. in Economics and Finance.
Aspinall is a healthcare industry leader and pioneer with a commitment to active civic involvement. She is Co-Founder and Managing Director of BlueStone Venture Partners, a venture fund investing in life sciences technology companies in the US Southwest. She is also CEO of the Health Catalysts Group, a consulting firm dedicated to the growth of health information technology and diagnostics firms. She is a member of the Board of Directors of Abcam plc (ABC), Allscripts (MDRX), Orasure (OSUR), Castle Biosciences (CSTL) and Blue Cross Blue Shield Arizona. Most recently, Aspinall was certified in Cybersecurity Oversight from Carnegie Mellon University. A leader in educating payers and policymakers on personalized medicine, she served on the Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in the Obama and Bush administrations. With a passion for education about the importance of diagnostics in healthcare, Aspinall co-founded the School of Biomedical Diagnostics at Arizona State University, the first and only program dedicated to Diagnostics as an independent discipline. Aspinall was named Arizona Biosciences Leader of the Year by the Arizona Biotechnology Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine. She started her business career at the strategic consulting firm Bain & Company. Aspinall holds an MBA from Harvard Business School and a BA from Tufts University.